Three insights:
1. Kuros will determine the use of Fibrin-PTH in single level transforaminal lumbar interbody fusion procedures in patients with degenerative disc disease, with autograft as the comparator.
2. Fibrin-PTH consists of a natural fibrin-based healing matrix with an immobilized targeted bone growth factor and is designed to apply onto and around an intervertebral body fusion device as a gel.
3. The primary endpoint of the trial is radiographic interbody fusion, using CT-scans at 12 months.
More articles on devices:
NASS unveils ’20 Under 40′ spine surgeons for 2019
Dr. Death to hit TV screens: A timeline of the former neurosurgeon’s case
How spine, neurosurgery departments are evolving — key thoughts from 4 leaders
